Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PHARMACY POINT-OF-PURCHASE IS OPPORTUNITY FOR PROVIDING PATIENT INFORMATION

Executive Summary

The point-of-purchase provides pharmacists with a "tremendous opportunity" for providing patients with drug and health information, FDA Com. Frank Young, MD/PhD, asserted May 1 at the Natl. Assn. of Chain Drug Stores (NACDS) annual meeting in Palm Beach, Fla. "A patient who is not feeling well is apt to be distracted and may not have complete recall -- hence the value of putting on the container the warning stickers we're all familiar with, or sharing any printed material that may be available on a particular medication," Young noted. The commissioner also pointed out pharmacists' ability to monitor medication through computerized recordkeeping. Young declared: "The drug store pharmacist has outstanding opportunities to obtain and communicate information, and I would urge all pharmacists to take advantage of these opportunities. The challenge before you is to demonstrate that a voluntary effort can get the job done." In his address, Young stressed the agency's current preference for voluntary and cooperative programs, such as the Natl. Council on Patient Information and Education, as first line efforts at filling public health information needs on Rx and OTC drugs. However, Young cautioned that the voluntary approach is on trial with the OTC analgesic industry's Reye's Syndrome label warning program. The labels are scheduled to appear on salicylate products this fall. "This will be a key test of voluntary compliance," Young told NACDS. "Next fall is not that far away, and concerted -- if not extraordinary -- effort will be needed to ensure that products are relabeled in time. We cannot underestimate the risk involved. If we fail, the future of voluntary compliance may be sadly compromised, and it will be difficult, if not impossible to use this regulatory approach -- which has so much to offer -- under similar circumstances again." The commissioner took the same message to the Proprietary Assn. The OTC mfrs. met the previous week. The agency's recently-proposed OTC labeling policy offers pharmacists an apportunity to provide a non-RX drug information service to patients, Young indicated. The proposed policy would create three different formats for displaying OTC drug claims and allow either FDA-approved wording or alternative language developed by mfrs. ("The Pink Sheet" April 22, p. 3).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel